What is the role of voclosporin in immunosuppression after pediatric transplantation?

Updated: Oct 18, 2019
  • Author: Randy P Prescilla, MD; Chief Editor: Mary C Mancini, MD, PhD, MMM  more...
  • Print


Novel calcineurin inhibitor

Voclosporin (VCS) is a novel calcineurin inhibitor being developed for organ transplantation. The PROMISE study, a 6-month, open-label, randomized, multicenter study, found that VCS was shown to be as effective as tacrolimus with similar rates of hypertension and adverse events, and no difference was noted in mycophenolic acid exposure. VCS did show excellent correlation between trough and area under the curve and was potentially associated with a reduced incidence of new-onset diabetes after transplantation. These results suggest that VSC may be a viable alternative to tacrolimus in preventing acute rejection. [6]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!